🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

High-Voltage Long-Duration Pulsed Radiofrequency Combined With Liposomal Bupivacaine Subcutaneous Block for Herpes Zoster-Associated Neuralgia

RecruitingPhase 4Ages 40 Years - 85 YearsAllShirong Tan
NCT06959147 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Research Objectives Background and Significance: Zoster-associated neuralgia (ZAN) refers to neuropathic pain experienced by herpes zoster (HZ) patients before, during, and after rash resolution, characterized by paroxysmal, lightning-like, or knife-like sensations. Postherpetic neuralgia (PHN), a common type of chronic pain, is often accompanied by physical-psychological impairments, social dysfunction, and anxiety-depression. While high-voltage long-term pulsed radiofrequency (HL-PRF) has become a conventional treatment for ZAN, it is limited by residual postoperative localized pain and suboptimal efficacy for refractory cases. Liposomal bupivacaine (LB), a sustained-release analgesic providing up to 72 hours of pain relief, offers potential for combined subcutaneous injection to enhance symptomatic control. Study Process: This clinical study focuses on evaluating the efficacy of HL-

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: Patients diagnosed with zoster-associated neuralgia (ZAN) who meet ALL of the following conditions: * Voluntarily provided written informed consent. * Inadequate response to pharmacological or other non-surgical therapies OR intolerable drug-related adverse effects. * Herpes zoster (HZ) lesions involving cranial/cervicocephalic, cervical, thoracic, or lumbar dermatomes. * Moderate-to-severe pain intensity, defined as a Numerical Rating Scale (NRS) score ≥4 at baseline. * Aged between 40 and 85 years. * Body weight: Male ≥50 kg; female ≥45 kg. Exclusion Criteria: * Severe cardiovascular diseases or life-threatening arrhythmias (e.g., heart failure, third-degree atrioventricular block without pacemaker implantation). * Contraindications to minimally invasive interventions (e.g., coagulation disorders, active infections). * Allergy to local anesthetics or lipid emulsions; Severe dysfunction of vital organs (cardiac, pulmonary, hepatic, or renal) rendering the patient unfit for the procedure. * Severe endocrine disorders or long-term use of corticosteroids/immunosuppressive agents. * Cognitive impairment or inability to cooperate with treatment protocols. * Prior history of neuromodulation therapies (e.g., spinal cord stimulation or pulsed radiofrequency (PRF) treatment).
💊

What it tests

  • High-Voltage Long-Duration Pulsed Radiofrequency plus Liposomal Bupivacaine group
  • High-Voltage Long-Duration Pulsed Radiofrequency
📍

Where

1 site
Affiliated Hospital of Zunyi Medical University
Zunyi, China
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy